IP Library › Granted Patent US 11,865,141
Granted Patent B2
US 11,865,141 · App. 16/959,366 · Granted Jan 9, 2024

Composition for improving, preventing or treating skin disease comprising induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon gamma and exosomes derived therefrom

Inventors: Sue Kim (Seoul, KR); Jin Ho Yu (Seoul, KR)
Assignees: THE ASAN FOUNDATION; UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
A61K35/28A61P17/00C12N5/0652
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,865,141
App. No.
16/959,366
Granted
Jan 9, 2024
Kind
B2
Abstract

The present invention may provide a method for producing induced pluripotency stem cell-derived mesenchymal stem cells (IFNγ-iMSC) pretreated with interferon-gamma; induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon-gamma prepared by the method; a pharmaceutical composition for preventing or treating skin diseases, and a cosmetic composition for preventing or improving skin diseases, comprising culture thereof or exosome (IFNγ-iMSC-exo) isolated therefrom as an active ingredient. When the composition of the present invention is used, it is possible to provide a composition for skin diseases and a stem cell therapeutic agent, which have an improved immunomodulating function over conventional mesenchymal stem cells.

Claims (4)

1. A method for treating or alleviating a skin disease selected from the group consisting of atopic dermatitis, contact dermatitis, and psoriasis, in a subject in need thereof, comprising:

administering to the subject a composition comprising (i) interferon-gamma-pretreated mesenchymal stem cells or a culture thereof, or (ii) exosomes isolated from interferon-gamma-pretreated mesenchymal stem cells or a culture thereof,

wherein the mesenchymal stem cells are induced pluripotent stem cell-derived mesenchymal stem cells (iMSC).

2. The method of claim 1 , wherein the subject is a mammal or a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2020
From: KIM, SUE; YU, JIN HO
To: THE ASAN FOUNDATION; UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
Reel/Frame 053248/0708 →
Priority Claims (1)
KR 10-2018-0001979 · Jan 5, 2018 · national
Continuity (1)
Related Publication 20210060081A1 · Mar 4, 2021